We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+72.28%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$94.7M
AUM Growth
+$3.27M
Cap. Flow
-$26.1M
Cap. Flow %
-27.54%
Top 10 Hldgs %
97.23%
Holding
20
New
3
Increased
3
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CRDF icon
Cardiff Oncology
CRDF
+$3.26M
2
GLD icon
SPDR Gold Trust
GLD
+$2.57M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$520K
4
SCYX icon
SCYNEXIS
SCYX
+$8.48K
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.54K

Top Sells

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$13.8M
2
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$12.5M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$3.38M
4
LITS
Lite Strategy Inc
LITS
+$1.79M
5
FSK icon
FS KKR Capital
FSK
+$511K

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Financials 0%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
1
DELISTED
Molecular Templates, Inc.
MTEM
$29.1M 30.68%
140,533
– –
SBBP
2
DELISTED
Strongbridge Biopharma plc.
SBBP
$25M 26.38%
6,612,065
– –
CRDF icon
3
Cardiff Oncology
CRDF
$59.8M
$7.99M 8.44%
+1,595,164
New +$3.26M
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.79M 8.22%
643,959
– –
KALA icon
5
KALA BIO
KALA
$15.7M
$6.52M 6.88%
248
-487
-66% -$13.8M
SCYX icon
6
SCYNEXIS
SCYX
$44.5M
$5.97M 6.3%
99,326
+125
+0.1% +$8.48K
GARS
7
DELISTED
Garrison Capital Inc.
GARS
$3.94M 4.15%
1,164,061
– –
GLD icon
8
SPDR Gold Trust
GLD
$130B
$2.67M 2.81%
+15,923
New +$2.57M
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$1.96M 2.07%
68,172
-538,148
-89% -$12.5M
LITS
10
Lite Strategy Inc
LITS
$33M
$1.22M 1.29%
14,778
-29,500
-67% -$1.79M
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$787K 0.83%
2,733
+12
+0.4% +$3.54K
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$719K 0.76%
619,460
+2,765
+0.4% +$2.92K
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$636K 0.67%
+124,771
New +$520K
KURA icon
14
Kura Oncology
KURA
$967M
$333K 0.35%
20,406
-1,896
-9% -$27.4K
ADXN
15
Addex Therapeutics
ADXN
$7.52M
$152K 0.16%
871
– –
CCAP icon
16
Crescent Capital BDC
CCAP
$413M
– –
-34,405
Closed -$332K
CLMT icon
17
Calumet Specialty Products
CLMT
$3.58B
– –
-131,204
Closed -$138K
FSK icon
18
FS KKR Capital
FSK
$3.11B
– –
-42,583
Closed -$511K
CBIO
19
Crescent Biopharma
CBIO
$417M
– –
-151
Closed -$34K
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-232,426
Closed -$3.38M

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2020 Portfolio in Review

As of Q2 2020, Caxton Corporation held 20 positions worth $94.7M, up 3.6% from $91.5M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Caxton Corporation withdrew a net $26.1M in Q2 2020, closing 5 positions and reducing 4 holdings. Its most notable exit was Viracta Therapeutics, Inc. Common Stock, an estimated $3.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 97% a quarter earlier, followed by Financials and Materials.

Against the trend, Caxton Corporation opened a new position in Cardiff Oncology worth $7.99M.

  • Caxton Corporation's largest Q2 2020 buy was Cardiff Oncology: 1,595,164 shares worth $7.99M.
  • Caxton Corporation added most to SCYNEXIS in Q2 2020, an estimated $8.48K increase.
  • Caxton Corporation's biggest Q2 2020 reduction was KALA BIO, cutting an estimated $13.8M.
  • Caxton Corporation fully exited Viracta Therapeutics, Inc. Common Stock in Q2 2020, selling an estimated $3.38M.
  • Caxton Corporation's ten largest holdings make up 97% of its $94.7M portfolio in Q2 2020.
  • Caxton Corporation opened 3 new positions and closed 5 in Q2 2020.
  • Caxton Corporation's portfolio value rose 3.6% quarter-over-quarter to $94.7M.

Based on Caxton Corporation's 13F filing for Q2 2020, filed 14 Aug 2020.